BioCryst partner seeks peramivir approval in Japan
BioCryst Pharma gets $7M payment after Japanese partner Shionogi files for marketing approval
- On 1:49 pm EST, Wednesday November 4, 2009
BIRMINGHAM, Ala. (AP) -- BioCryst Pharmaceuticals Inc. said Wednesday its partner Shionogi & Co. filed for approval to market BioCryst's IV flu drug peramivir in Japan.
Shionogi's filing triggers a $7 million milestone payment to BioCryst.
Peramivir is an intravenous drug intended to treat the flu in patients who are hospitalized, and too sick to take an oral treatment. The government has authorized use of peramivir as a treatment for the swine flu, but clinical testing is expected to continue until 2011.
In afternoon trading, BioCryst stock rose 79 cents, or 8.5 percent, to $10.10.
Related Headlines
- BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events - EDGAR Online
- BioCryst prices stock offering at $9.75 per share - AP
- BioCryst Announces Pricing of Public Offering of Common Stock - PR Newswire
- Big Pullback for Top Swine Flu Small-Caps - Indie Research
- Pharmaceutical Companies Shift Drug Development Away From Blockbuster Treatments In Response To FDA Concerns According To Morningstar Analyst - Wall Street Transcript
Related Blog Headlines
- Short Blood Supply Means Long Outlook for Cerus - at Seeking Alpha
- Thursday Options Recap - at Seeking Alpha
- Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork? - at Seeking Alpha
- Tuesday Options Recap - at Seeking Alpha
- Equities Update: Oil Drops, Stocks Too - at Seeking Alpha
Sponsored Links
-
Trade Stocks? Try Currency Trading
Trade in a highly trending market 24-hrs a day, 5.5 days a week. GFT. -
Earn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
-
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today. -
Super Cheap Car Insurance Quotes
Get Discount Auto Insurance Quotes Online - Rates from $15 / Month.
Tech Ticker Recent Posts
Add Alert Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.